ArticleFrontiers in cardiovascular medicine2023
Machine learning approaches for cardiovascular hypertension stage estimation using photoplethysmography and clinical features.
Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Predicting the Risk of Cardiovascular Diseases in the Elderly Based on Clinical Data and Heart Rate Variability Using Machine Learning.Journal of clinical medicine · 2026Article
- Towards trustworthy AI-driven cuffless blood pressure monitoring.NPJ digital medicine · 2026Article
- Exploring hemodynamic measurements from the Tromsø Study for prediction of cardiovascular disease using traditional statistical models and machine learning approaches.Scientific reports · 2026Article
- The insulin resistance-systemic vascular resistance-isolated diastolic hypertension axis: a metabolic framework for an overlooked hypertension phenotype.Frontiers in cardiovascular medicine · 2026Review
- Photoplethysmography acceleration indices as digital biomarkers of cardiometabolic health.Frontiers in digital health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) are a leading cause of death worldwide, with hypertension emerging as a significant risk factor. Early detection and treatment of hypertension can significantly reduce the risk of developing CVDs and related complications. This work proposes a novel approach employing features extracted from the acceleration photoplethysmography (APG) waveform, alongside clinical parameters, to estimate different stages of hypertension. The current study used a publicly available dataset and a novel feature extraction algorithm to extract APG waveform features. Three distinct supervised machine learning algorithms were employed in the classification task, namely: Decision Tree (DT), Linear Discriminant Analysis (LDA), and Linear Support Vector Machine (LSVM). Results indicate that the DT model achieved exceptional training accuracy of 100% during cross-validation and maintained a high accuracy of 96.87% on the test dataset. The LDA model demonstrated competitive performance, yielding 85.02% accuracy during cross-validation and 84.37% on the test dataset. Meanwhile, the LSVM model exhibited robust accuracy, achieving 88.77% during cross-validation and 93.75% on the test dataset. These findings underscore the potential of APG analysis as a valuable tool for clinicians in estimating hypertension stages, supporting the need for early detection and intervention. This investigation not only advances hypertension risk assessment but also advocates for enhanced cardiovascular healthcare outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.